ME Therapeutics Holdings Inc. (CSE:METX)

ME Therapeutics Holdings Income Statement

Financials in millions CAD. Fiscal year is September - August.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Nov 30, 2025	Aug 31, 2025	Aug 31, 2024	Aug 31, 2023	Aug 31, 2022	Aug 31, 2021
Selling, General & Admin	0.72	0.61	0.37	0.36	0.08	0.04
Research & Development	0.51	0.41	0.31	0.03	0.05	-
Operating Expenses	1.35	1.28	1.37	0.98	0.15	0.07
Operating Income	-1.35	-1.28	-1.37	-0.98	-0.15	-0.07
Interest Expense	-0.01	-0.01	-	-0.01	-0.01	-
Interest & Investment Income	0.03	0.04	0.03	0.01	-	-
Other Non Operating Income (Expenses)	0.08	0.06	0.05	-	0.02	-
EBT Excluding Unusual Items	-1.25	-1.19	-1.29	-0.97	-0.15	-0.07
Other Unusual Items	-	-	-	-5.55	-	-
Pretax Income	-1.25	-1.19	-1.29	-6.52	-0.15	-0.07
Net Income	-1.25	-1.19	-1.29	-6.52	-0.15	-0.07
Net Income to Common	-1.25	-1.19	-1.29	-6.52	-0.15	-0.07
Shares Outstanding (Basic)	29	28	24	16	8	6
Shares Outstanding (Diluted)	29	28	24	16	8	6
Shares Change (YoY)	16.94%	14.17%	55.90%	84.08%	39.53%	0.07%
EPS (Basic)	-0.04	-0.04	-0.05	-0.42	-0.02	-0.01
EPS (Diluted)	-0.04	-0.04	-0.05	-0.42	-0.02	-0.01
Free Cash Flow	-1.25	-1.08	-0.66	-0.3	-0.14	0
Free Cash Flow Per Share	-0.04	-0.04	-0.03	-0.02	-0.02	0.00
EBITDA	-1.32	-1.24	-1.37	-0.98	-0.15	-0.07
D&A For EBITDA	0.03	0.03	0	0	0	0
EBIT	-1.35	-1.28	-1.37	-0.98	-0.15	-0.07

Updated Nov 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.